By Chris Wack

Eli Lilly and Co. said tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from its clinical trial.

The pharmaceutical company said the results showed that all three tirzepatide doses achieved greater A1C and weight reductions compared to semaglutide.

A prespecified exploratory composite endpoint comprised of participants who achieved an A1C level less than or equal to 6.5% percent and weight loss of 10% or more, while not experiencing hypoglycemia less than 54 mg/dL or severe hypoglycemia, was evaluated.

Across the three doses of tirzepatide, 32% of 5 mg, 51% of 10 mg and 60% of 15 mg of participants achieved this composite endpoint compared to 22% of participants taking semaglutide 1 mg.

The overall safety profile of tirzepatide was similar to the well-established glucagon-like peptide-1 receptor agonist class. Across all treatment arms, the most commonly reported adverse events were gastrointestinal-related.

In an additional exploratory endpoint, all three doses of tirzepatide led to favorable changes from baseline in fasting lipids.

Lilly intends to submit the full registration package to regulatory authorities by the end of 2021.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

06-25-21 1201ET